Michael A. Howard, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 |
Dr. Anthony Paul Terrasse, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 700 N Westmoreland Rd, Building D, Lake Forest, IL 60045 Phone: 847-234-2400 Fax: 847-234-2470 |
Sylvia Joanna Wier, FNP-C Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 847-234-5600 |
Brianna Nicole Selimos, PHYSICIAN ASSISTANT Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 224-271-4250 |
Dr. Chad Michael Teven, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1000 N Westmoreland Rd, Lake Forest, IL 60045 Phone: 312-694-7337 Fax: 312-695-9116 |
News Archive
ANI Pharmaceuticals, Inc. today announced that it has acquired the approved abbreviated new drug application ("ANDA") for Flecainide Acetate tablets USP 50mg, 100mg and 150mg, previously marketed by Teva Pharmaceuticals.
Whole-exome DNA sequencing - a technology that saves time and money by sequencing only protein-coding regions and not the entire genome - may routinely miss detecting some genetic variations associated with disease, according to Penn State researchers who have developed new ways to identify such omissions.
Clemson University has established the first program to train engineers to recycle and reprocess medical devices. The Medical Device Recycling and Reprocessing Certificate Program offered by the Clemson University Biomedical Engineering Innovation Campus (CUBEInC) was developed in response to the dramatic market adoption of reprocessing in recent years.
Dr Clare Scott from the Walter and Eliza Hall Institute in Melbourne, Australia, has been awarded a Victorian Cancer Agency (VCA) Clinical Fellowship to further research into an aggressive and highly lethal form of ovarian cancer.
Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).
› Verified 5 days ago